1. Mohan, N, Edwards, ET, Cupps, TR, et al. Demyelination occurring during anti-tumor necrosis factor α therapy for inflammatory arthritides. Arthritis Rheum 2001; 44: 2862–2869.
Google Scholar | Crossref | Medline2. Andreadou, E, Kemanetzoglou, E, Sfakianaki, K, et al. Demyelinating disease following anti-TNF-alpha treatment. A causal or coincidental association? Report of two cases. Eur J Neurol 2012; 19: 714. http://bf4dv7zn3u.search.serialssolutions.com.myaccess.library.utoronto.ca/?url_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rfr_id=info:sid/Ovid:emed10&rft.genre=article&rft_id=info:doi/10.1111%2Fj.1468-1331.2012.03889.x&rft_id=info:pmid/&rft.
Google Scholar3. Kemanetzoglou, E, Andreadou, E. CNS Demyelination with TNF-α blockers. Curr Neurol Neurosci Rep 2017; 17(4): 36.
Google Scholar4. Arnason, BGW . TNF Neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 1999; 53: 457–465.
Google Scholar | Crossref | Medline5. Kunchok, A, Aksamit, AJ, Davis, JM, et al. Association between tumor necrosis factor inhibitor exposure and inflammatory central nervous system events. JAMA Neurol 2020; 77: 937–946.
Google Scholar | Crossref | Medline6. Van Vollenhoven, R, Harju, A, Brannemark, S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor α blockers can make sense. Ann Rheum Dis 2003; 62: 1195–1198.
Google Scholar | Crossref | Medline | ISI7. Mpofu, S, Fatima, F, Moots, RJ. Anti-TNF-α therapies: they are all the same (aren’t they?) Rheumatology 2005; 44: 271–273.
Google Scholar | Crossref | Medline8. Abushouk, AI, Ahmed, H, Ismail, A, et al. Safety and efficacy of ocrelizumab in rheumatoid arthritis patients with an inadequate response to methotrexate or tumor necrosis factor inhibitors: a systematic review and meta-analysis. Rheumatol Int 2017; 37: 1053–1064.
Google Scholar | Crossref | Medline9. Cohen, JD . Successful treatment of psoriatic arthritis with rituximab. Ann Rheum Dis 2008; 67: 1647–1648.
Google Scholar | Crossref | Medline | ISI10. Wendling, D, Dougados, M, Berenbaum, F, et al. Rituximab treatment for spondyloarthritis. A nationwide series: data from the AIR registry of the French society of rheumatology. J Rheumatol 2012; 39: 2327–2331.
Google Scholar | Crossref | Medline | ISI11. Sandborn, WJ, Colombel, JF, Enns, R, et al. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912–1925.
Google Scholar | Crossref | Medline | ISI12. Ford, AC, Sandborn, WJ, Khan, KJ, et al. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644–659.
Google Scholar | Crossref | Medline | ISI13. Tintoré, M, Rovira, A, Río, J, et al. Do oligoclonal bands add information to MRI in first attacks of multiple sclerosis? Neurology 2008; 70: 1079–1083.
Google Scholar | Crossref | Medline | ISI